Selected research
Industry Research
Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Industry Research Report 2026
Market perspective
The global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 include Takeda, Jiangsu Hengrui Medicine Co Ltd, Jiangsu Nhwa Pharmaceutical Corp Ltd, Pfizer Inc, Primex Pharmaceuticals Oy and Paion AG, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Gamma-Aminobutyric Acid Receptor Subunit Gamma 2.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market by Company
Takeda
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Nhwa Pharmaceutical Corp Ltd
Pfizer Inc
Primex Pharmaceuticals Oy
Paion AG
Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Segment by Type
EL-001
Midazolam Hydrochloride
LASSBio-786
LASSBio-785
Others
Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Segment by Application
Insomnia
General Anesthetic Effect
Hypertension
Others
Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gamma-Aminobutyric Acid Receptor Subunit Gamma 2.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- EL-001
- Midazolam Hydrochloride
- LASSBio-786
- LASSBio-785
- Others
Applications
- Insomnia
- General Anesthetic Effect
- Hypertension
- Others
Companies covered
- Takeda
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Nhwa Pharmaceutical Corp Ltd
- Pfizer Inc
- Primex Pharmaceuticals Oy
- Paion AG
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 EL-001
- 2.2.3 Midazolam Hydrochloride
- 2.2.4 LASSBio-786
- 2.2.5 LASSBio-785
- 2.2.6 Others
- 2.3 Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Insomnia
- 2.3.3 General Anesthetic Effect
- 2.3.4 Hypertension
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Breakdown Data by Type
- 3.1 Global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Historic Market Size by Type (2021-2026)
- 3.2 Global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Forecasted Market Size by Type (2027-2032)
4 Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Breakdown Data by Application
- 4.1 Global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Historic Market Size by Application (2021-2026)
- 4.2 Global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Perspective (2021-2032)
- 5.2 Global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Growth Trends by Region
- 5.2.1 Global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Historic Market Size by Region (2021-2026)
- 5.2.3 Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Forecasted Market Size by Region (2027-2032)
- 5.3 Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Dynamics
- 5.3.1 Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Industry Trends
- 5.3.2 Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Drivers
- 5.3.3 Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Challenges
- 5.3.4 Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Players by Revenue
- 6.1.1 Global Top Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Players by Revenue (2021-2026)
- 6.1.2 Global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Revenue Market Share by Players (2021-2026)
- 6.2 Global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Head Office and Area Served
- 6.4 Global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Players, Product Type & Application
- 6.5 Global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Manufacturers Established Date
- 6.6 Global Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Size (2021-2032)
- 7.2 North America Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Size by Country (2021-2026)
- 7.4 North America Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Size (2021-2032)
- 8.2 Europe Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Size by Country (2021-2026)
- 8.4 Europe Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Size (2021-2032)
- 9.2 Asia-Pacific Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Size (2021-2032)
- 10.2 South America Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Size by Country (2021-2026)
- 10.4 South America Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Size (2021-2032)
- 11.2 Middle East & Africa Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda
- 12.1.1 Takeda Company Information
- 12.1.2 Takeda Business Overview
- 12.1.3 Takeda Revenue in Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Business (2021-2026)
- 12.1.4 Takeda Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Product Portfolio
- 12.1.5 Takeda Recent Developments
- 12.2 Jiangsu Hengrui Medicine Co Ltd
- 12.2.1 Jiangsu Hengrui Medicine Co Ltd Company Information
- 12.2.2 Jiangsu Hengrui Medicine Co Ltd Business Overview
- 12.2.3 Jiangsu Hengrui Medicine Co Ltd Revenue in Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Business (2021-2026)
- 12.2.4 Jiangsu Hengrui Medicine Co Ltd Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Product Portfolio
- 12.2.5 Jiangsu Hengrui Medicine Co Ltd Recent Developments
- 12.3 Jiangsu Nhwa Pharmaceutical Corp Ltd
- 12.3.1 Jiangsu Nhwa Pharmaceutical Corp Ltd Company Information
- 12.3.2 Jiangsu Nhwa Pharmaceutical Corp Ltd Business Overview
- 12.3.3 Jiangsu Nhwa Pharmaceutical Corp Ltd Revenue in Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Business (2021-2026)
- 12.3.4 Jiangsu Nhwa Pharmaceutical Corp Ltd Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Product Portfolio
- 12.3.5 Jiangsu Nhwa Pharmaceutical Corp Ltd Recent Developments
- 12.4 Pfizer Inc
- 12.4.1 Pfizer Inc Company Information
- 12.4.2 Pfizer Inc Business Overview
- 12.4.3 Pfizer Inc Revenue in Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Business (2021-2026)
- 12.4.4 Pfizer Inc Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Product Portfolio
- 12.4.5 Pfizer Inc Recent Developments
- 12.5 Primex Pharmaceuticals Oy
- 12.5.1 Primex Pharmaceuticals Oy Company Information
- 12.5.2 Primex Pharmaceuticals Oy Business Overview
- 12.5.3 Primex Pharmaceuticals Oy Revenue in Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Business (2021-2026)
- 12.5.4 Primex Pharmaceuticals Oy Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Product Portfolio
- 12.5.5 Primex Pharmaceuticals Oy Recent Developments
- 12.6 Paion AG
- 12.6.1 Paion AG Company Information
- 12.6.2 Paion AG Business Overview
- 12.6.3 Paion AG Revenue in Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Business (2021-2026)
- 12.6.4 Paion AG Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 Product Portfolio
- 12.6.5 Paion AG Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst